A federal appeals court blocked mailing of mifepristone, requiring in-person clinic distribution and overruling FDA rules. The unanimous 5th Circuit ruling, a win for abortion opponents, is expected to be appealed to the Supreme Court, affecting states beyond bans.
Comments